152 related articles for article (PubMed ID: 35215926)
1. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals.
Chen YC; Chang TS; Chen CH; Cheng PN; Lo CC; Mo LR; Chen CT; Huang CF; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Dai CY; Kao JH; Chuang WL; Lin HC; Chen CY; Tseng KC; Yu ML; On Behalf Of Tacr Investigators
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215926
[TBL] [Abstract][Full Text] [Related]
2. Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents.
Chen YC; Tseng CW; Tseng KC
Medicine (Baltimore); 2020 May; 99(19):e20156. PubMed ID: 32384505
[TBL] [Abstract][Full Text] [Related]
3. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
Hsu WF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
BMC Gastroenterol; 2019 Apr; 19(1):63. PubMed ID: 31029101
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
5. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
6. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.
Honma Y; Shibata M; Hayashi T; Kusanaga M; Ogino N; Minami S; Kumei S; Oe S; Miyagawa K; Senju M; Matsuoka H; Watanabe T; Hiura M; Abe S; Harada M
Liver Int; 2019 Sep; 39(9):1641-1651. PubMed ID: 31009141
[TBL] [Abstract][Full Text] [Related]
7. Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy.
Chen YC; Ko PH; Lee CC; Tseng CW; Tseng KC
BMC Gastroenterol; 2021 Jan; 21(1):30. PubMed ID: 33478399
[TBL] [Abstract][Full Text] [Related]
8. Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy.
Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2018 May; 33(5):1108-1114. PubMed ID: 29023927
[TBL] [Abstract][Full Text] [Related]
9. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
Lin KH; Hsu PI; Yu HC; Lin CK; Tsai WL; Chen WC; Chan HH; Lai KH
BMC Gastroenterol; 2012 Jan; 12():7. PubMed ID: 22257364
[TBL] [Abstract][Full Text] [Related]
10. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
[TBL] [Abstract][Full Text] [Related]
11. The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals.
Seko Y; Moriguchi M; Takahashi A; Okishio S; Kataoka S; Okuda K; Mizuno N; Takemura M; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Intern Med; 2020; 59(15):1811-1817. PubMed ID: 32741890
[TBL] [Abstract][Full Text] [Related]
12. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.
Kee KM; Wang JH; Hung CH; Chen CH; Lee CM; Lu SN
Dig Dis Sci; 2013 Feb; 58(2):556-61. PubMed ID: 23001404
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
14. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
15. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection.
Nakajima T; Karino Y; Hige S; Suii H; Tatsumi R; Yamaguchi M; Arakawa T; Kuwata Y; Toyota J
Ann Hepatol; 2022; 27(1):100566. PubMed ID: 34688887
[TBL] [Abstract][Full Text] [Related]
16. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
17. Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma.
Huynh T; Hu KQ
Front Med; 2019 Dec; 13(6):658-666. PubMed ID: 31655955
[TBL] [Abstract][Full Text] [Related]
18. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
19. Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis.
Sayyar M; Saidi M; Zapatka S; Deng Y; Ciarleglio M; Garcia-Tsao G
Liver Int; 2019 Nov; 39(11):2061-2065. PubMed ID: 31365178
[TBL] [Abstract][Full Text] [Related]
20. Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals.
Benetti F; de Araújo A; de Maman Júnior I; Coelho Borges Cheinquer C; Herz Wolff F; Cheinquer H
Arch Endocrinol Metab; 2024 May; 68():e220480. PubMed ID: 38709148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
